Advertisement

Topics

Idorsia reports positive results from Phase II programme of insomnia drug

19:00 EDT 31 Jul 2017 | Net Resources International

Swiss biopharmaceutical firm Idorsia has reported positive results from a Phase II programme of ACT-541468 to treat patients suffering from insomnia.

Original Article: Idorsia reports positive results from Phase II programme of insomnia drug

NEXT ARTICLE

More From BioPortfolio on "Idorsia reports positive results from Phase II programme of insomnia drug"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...